---
title: "Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Clinical trials questions"
description: "Clinical trials questions on Xarelto (rivaroxaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Interpreting study results, and Subgroup results. Questions: Xarelto vs warfarin: how did stroke risk compare in ROCKET AF? Was Xarelto superior to warfarin in ROCKET AF? Does Xarelto cause more bleeding than warfarin (ROCKET AF)? Xarelto 15 mg in moderate kidney impairment: what were the ROCKET AF results? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Clinical trials questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)

Questions that apply to every indication of Xarelto are on [Xarelto (rivaroxaban), all indications](https://www.evicenter.com/medical-information/xarelto).

## Study results

<a id="xarelto-rocket-af-stroke"></a>

### Xarelto vs warfarin: how did stroke risk compare in ROCKET AF?

> “The evidence for the efficacy and safety of XARELTO was derived from 
> Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K 
> antagonist for the prevention of stroke and Embolism Trial in Atrial Fibrillation 
> (ROCKET AF) [NCT00403767], a multi-national, double-blind study comparing 
> XARELTO (at a dose of 20 mg once daily with the evening meal in patients with 
> CrCl >50 mL/min and 15 mg once daily with the evening meal in patients with 
> CrCl 30 to 50 mL/min) to warfarin (titrated to INR 2.0 to 3.0) to reduce the risk of 
> stroke and non-central nervous system (CNS) systemic embolism in patients with 
> nonvalvular atrial fibrillation (AF). Patients had to have one or more of the 
> following additional risk factors for stroke:
> •	 a prior stroke (ischemic or unknown type), transient ischemic attack (TIA) or 
> non-CNS systemic embolism, or
> •	 2 or more of the following risk factors:
> °	age ≥75 years,
> °	hypertension,
> °	heart failure or left ventricular ejection fraction ≤35%, or
> °	diabetes mellitus
> ROCKET AF was a non-inferiority study designed to demonstrate that XARELTO 
> preserved more than 50% of warfarin’s effect on stroke and non-CNS systemic 
> embolism as established by previous placebo-controlled studies of warfarin in 
> atrial fibrillation.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

> “A total of 14264 patients were randomized and followed on study treatment for a 
> median of 590 days. The mean age was 71 years and the mean CHADS2 score was 
> 3.5. The population was 60% male, 83% Caucasian, 13% Asian and 1.3% Black. 
> There was a history of stroke, TIA, or non-CNS systemic embolism in 55% of 
> patients, and 38% of patients had not taken a vitamin K antagonist (VKA) within 
> 6 weeks at time of screening. Concomitant diseases of patients in this study 
> included hypertension 91%, diabetes 40%, congestive heart failure 63%, and prior 
> myocardial infarction 17%. At baseline, 37% of patients were on aspirin (almost 
> exclusively at a dose of 100  mg or less) and few patients were on clopidogrel. 
> Patients were enrolled in Eastern Europe (39%); North America (19%); Asia, 
> Australia, and New Zealand (15%); Western Europe (15%); and Latin America 
> (13%). Patients randomized to warfarin had a mean percentage of time in the INR 
> target range of 2.0 to 3.0 of 55%, lower during the first few months of the study.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

> “In ROCKET AF, XARELTO was demonstrated non-inferior to warfarin for the 
> primary composite endpoint of time to first occurrence of stroke (any type) or 
> non-CNS systemic embolism [HR  (95% CI): 0.88 (0.74, 1.03)], but superiority to 
> warfarin was not demonstrated. There is insufficient experience to determine 
> how XARELTO and warfarin compare when warfarin therapy is well-controlled.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

> “Table 19:  Primary Composite Endpoint Results in ROCKET AF Study (Intent-to-
> Treat Population)
> XARELTO
> Warfarin
> XARELTO 
> vs. 
> Warfarin
> Event
> N=7081
> n (%)
> Event Rate
> (per 100 
> Pt-yrs)
> N=7090
> n (%)
> Event Rate
> (per 100 
> Pt-yrs)
> Hazard 
> Ratio
> (95% CI)
> Primary Composite 
> Endpoint* 
> 269 (3.8)
> 2.1
> 306 (4.3)
> 2.4
> 0.88 
> (0.74, 1.03)
> Stroke 
> 253 (3.6)
> 2.0
>  281 (4.0)
> 2.2
> Hemorrhagic 
> Stroke<sup>†</sup>
> 33 (0.5) 
> 0.3 
> 57 (0.8)
> 0.4
> Ischemic Stroke
> 206 (2.9)
> 1.6
> 208 (2.9) 
> 1.6 
> Unknown Stroke 
> Type
> 19 (0.3)
> 0.2
> 18 (0.3) 
> 0.1
> Non-CNS Systemic 
> Embolism
> 20 (0.3) 
> 0.2
> 27 (0.4)
> 0.2”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

> “<sup>*</sup>	 The primary endpoint was the time to first occurrence of stroke (any type) or non-
> CNS systemic embolism. Data are shown for all randomized patients followed to 
> site notification that the study would end.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

Note: In Table 19 each row gives XARELTO (N=7081) n (%) and event rate per 100 patient-years, then warfarin (N=7090) n (%) and event rate, then the hazard ratio (95% CI) where one is given. ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.

<a id="xarelto-rocket-af-bleeding"></a>

### Does Xarelto cause more bleeding than warfarin (ROCKET AF)?

> “In the ROCKET AF trial, the most frequent adverse reactions associated with 
> permanent drug discontinuation were bleeding events, with incidence rates of 
> 4.3% for XARELTO vs. 3.1% for warfarin. The incidence of discontinuations for 
> non-bleeding adverse events was similar in both treatment groups.”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

> “Table 5:  Bleeding Events in ROCKET AF*- On Treatment Plus 2 Days
> Parameter
> XARELTO
> N=7111
> n (%/year)
> Warfarin
> N=7125
> n (%/year)
> XARELTO vs. Warfarin
> HR 
> (95% CI)
> Major Bleeding<sup>†</sup>
> 395 (3.6)
> 386 (3.5)
> 1.04 (0.90, 1.20)
> Intracranial  
> Hemorrhage (ICH) <sup>‡</sup>
> 55 (0.5)
> 84 (0.7)
> 0.67 (0.47, 0.93)
> Hemorrhagic Stroke<sup>§</sup>
> 36 (0.3)
> 58 (0.5)
> 0.63 (0.42, 0.96)
> Other ICH
> 19 (0.2)
> 26 (0.2)
> 0.74 (0.41, 1.34)
> Gastrointestinal (GI)<sup>¶</sup>
> 221 (2.0)
> 140 (1.2)
> 1.61 (1.30, 1.99)
> Fatal Bleeding<sup>#</sup> 
> 27 (0.2)
> 55 (0.5)
> 0.50 (0.31, 0.79)
> ICH
> 24 (0.2)
> 42 (0.4)
> 0.58 (0.35, 0.96)
> Non-intracranial
> 3 (0.0)
> 13 (0.1)
> 0.23 (0.07, 0.82)”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

> “<sup>*</sup>	 Major bleeding events within each subcategory were counted once per 
> patient, but patients may have contributed events to multiple subcategories. 
> These events occurred during treatment or within 2 days of stopping treatment.
> <sup>†</sup>	 Defined as clinically overt bleeding associated with a decrease in hemoglobin 
> of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, 
> bleeding at a critical site, or with a fatal outcome.
> <sup>‡</sup>	 Intracranial bleeding events included intraparenchymal, intraventricular, 
> subdural, subarachnoid and/or epidural hematoma.
> <sup>§</sup>	 Hemorrhagic stroke in this table specifically refers to non-traumatic 
> intraparenchymal and/or intraventricular hematoma in patients on treatment 
> plus 2 days.
> <sup>¶</sup>	 Gastrointestinal bleeding events included upper GI, lower GI, and rectal bleeding.
> <sup>#</sup>	 Fatal bleeding is adjudicated death with the primary cause of death from bleeding.”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

Note: In Table 5 each row gives XARELTO (N=7111) n (%/year), warfarin (N=7125) n (%/year), and the hazard ratio (95% CI). The atrial fibrillation page of the Xarelto HCP site, as captured on November 13, 2026, shows the non-intracranial fatal bleeding confidence interval as 0.07-0.32; the Prescribing Information gives (0.07, 0.82). ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.

<a id="xarelto-cardioversion"></a>

### Has Xarelto been studied for cardioversion in atrial fibrillation?

> “Few patients in ROCKET AF underwent electrical cardioversion for atrial 
> fibrillation. The utility of XARELTO for preventing post-cardioversion stroke and 
> systemic embolism is unknown.”

Source: [XARELTO: Prescribing information, page 15, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=15)

## Interpreting study results

<a id="xarelto-rocket-af-superiority"></a>

### Was Xarelto superior to warfarin in ROCKET AF?

> “In ROCKET AF, XARELTO was demonstrated non-inferior to warfarin for the 
> primary composite endpoint of time to first occurrence of stroke (any type) or 
> non-CNS systemic embolism [HR  (95% CI): 0.88 (0.74, 1.03)], but superiority to 
> warfarin was not demonstrated. There is insufficient experience to determine 
> how XARELTO and warfarin compare when warfarin therapy is well-controlled.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

> “XARELTO® demonstrated noninferiority vs warfarin, but superiority was not established.”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=XARELTO%C2%AE%20demonstrated%20noninferiority%20vs%20warfarin%2C%20but%20superiority%20was%20not%20established.)

> “The conventional method for establishing superiority is in the ITT population using data from all patients who were randomized to treatment, and this analysis did not support the superiority of XARELTO® to warfarin<sup>6</sup>”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=The%20conventional%20method%20for%20establishing,the%20superiority%20of%20XARELTO%C2%AE%20to)

> “A superiority analysis was conducted in the safety population during treatment (safety, as-treated population), which included patients who received at least 1 dose of study drug and were followed for events, while they were receiving treatment or within 2 days after discontinuation<sup>1</sup>”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=A%20superiority%20analysis%20was%20conducted,or%20within%202%20days%20after)

> “XARELTO® demonstrated noninferiority versus warfarin, but superiority was seen in the safety, as-treated population. There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and SE when warfarin therapy is well controlled<sup>1</sup>”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=XARELTO%C2%AE%20demonstrated%20noninferiority%20versus%20warfarin%2C,when%20warfarin%20therapy%20is%20well)

> “†Superiority was achieved in the safety, as-treated population in a secondary analysis of patients taking at least 1 dose of XARELTO®. The ITT population demonstrated noninferiority.”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=%E2%80%A0Superiority%20was%20achieved%20in%20the,The%20ITT%20population%20demonstrated%20noninferiority.)

Note: The first passage is from the Prescribing Information; the others are from the atrial fibrillation page of the Xarelto HCP site. ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.

## Subgroup results

<a id="xarelto-rocket-af-kidney"></a>

### Xarelto 15 mg in moderate kidney impairment: what were the ROCKET AF results?

> “In ROCKET AF, 21% (n=2950) of the study population had moderate renal impairment (CrCl 30 to 49 mL/min) at the time of enrollment.<sup>4</sup>  The dose of XARELTO® in these patients was 15 mg once daily, taken with the evening meal. The findings in these patients were consistent with those who had better renal function (CrCl ≥50 mL/min) and with the overall ROCKET AF trial results. These patients had a median age of 79 years; a mean CHADS2 score of 3.7, reflecting an increased risk for stroke; and a higher prevalence of heart failure, peripheral vascular disease, and prior MI than those with better renal function.<sup>4</sup>”

Source: [XARELTO: Frequently Asked Questions (FAQs), captured 2026-11-13](https://www.xareltohcp.com/faqs/#general-questions:~:text=In%20ROCKET%20AF%2C%2021%25%20%28n%3D2950%29,than%20those%20with%20better%20renal)

This passage is in a collapsed section of the page; select: What were the clinical results for patients with moderate renal impairment receiving a 15-mg dose of XARELTO®?

> “Efficacy and safety results in patients with moderate renal impairment (CrCl 30 to 49 mL/min) receiving XARELTO® 15 mg once daily were generally consistent with those with better renal function (CrCl ≥50 mL/min) given XARELTO®  20 mg once daily, and consistent with the overall trial.<sup>4</sup>”

Source: [XARELTO: Frequently Asked Questions (FAQs), captured 2026-11-13](https://www.xareltohcp.com/faqs/#general-questions:~:text=Efficacy%20and%20safety%20results%20in,and%20consistent%20with%20the%20overall)

This passage is in a collapsed section of the page; select: What were the clinical results for patients with moderate renal impairment receiving a 15-mg dose of XARELTO®?

Note: This is a subgroup analysis of ROCKET AF (Fox et al., Eur Heart J 2011, cited on the FAQ page); the comparator in each renal subgroup was warfarin.

## Related pages
- [Medical information: Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/indication)
- [Real-world evidence](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/guidelines)
